Jung Sung-Hoon, Koh Youngil, Kim Min Kyoung, Kim Jin Seok, Moon Joon Ho, Min Chang-Ki, Yoon Dok Hyun, Yoon Sung-Soo, Lee Je-Jung, Hong Chae Moon, Kang Ka-Won, Kwon Jihyun, Kim Kyoung Ha, Kim Dae Sik, Kim Sung Yong, Kim Sung-Hyun, Kim Yu Ri, Do Young Rok, Mun Yeung-Chul, Park Sung-Soo, Park Young Hoon, Shin Ho Jin, Eom Hyeon-Seok, Yoon Sang Eun, Hwang Sang Mee, Lee Won Sik, Lee Myung-Won, Yi Jun Ho, Lee Ji Yun, Lee Ji Hyun, Lee Ho Sup, Lim Sung-Nam, Lim Jihyang, Yhim Ho-Young, Chang Yoon Hwan, Jo Jae-Cheol, Cho Jinhyun, Cho Hyungwoo, Choi Yoon Seok, Cho Hee Jeong, Ahn Ari, Choi Jong Han, Kim Hyun Jung, Kim Kihyun
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Republic of Korea.
Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Blood Res. 2025 Feb 4;60(1):9. doi: 10.1007/s44313-025-00055-9.
Multiple myeloma (MM), a hematological malignancy, is characterized by malignant plasma cell proliferation in the bone marrow. Recent treatment advances have significantly improved patient outcomes associated with MM. In this study, we aimed to develop comprehensive, evidence-based guidelines for the diagnosis, prognosis, and treatment of MM. We identified 12 key clinical questions essential for MM management, guiding the extensive literature review and meta-analysis of the study. Our guidelines provide evidence-based recommendations by integrating patient preferences with survey data. These recommendations include current and emerging diagnostic tools, therapeutic agents, and treatment strategies. By prioritizing a patient-centered approach and rigorous data analysis, these guidelines were developed to enhance MM management, both in Korea and globally.
多发性骨髓瘤(MM)是一种血液系统恶性肿瘤,其特征是骨髓中恶性浆细胞增殖。最近的治疗进展显著改善了与MM相关的患者预后。在本研究中,我们旨在制定关于MM诊断、预后和治疗的全面、循证指南。我们确定了12个对MM管理至关重要的关键临床问题,以指导本研究的广泛文献综述和荟萃分析。我们的指南通过将患者偏好与调查数据相结合,提供了循证建议。这些建议包括当前和新兴的诊断工具、治疗药物和治疗策略。通过优先采用以患者为中心的方法和严格的数据分析,制定这些指南是为了在韩国和全球范围内加强MM的管理。